Lanean...
Racial Disparities in the Utilization of Novel Agents for Front-line Treatment of Multiple Myeloma
BACKGROUND: Treatment with novel agents has become the standard-of-care for newly diagnosed multiple myeloma, but members of racial and ethnic minority groups receive these agents at a lower rate than their peers. Researchers have largely attributed this finding to the higher costs of these drugs in...
Gorde:
| Argitaratua izan da: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8247682/ https://ncbi.nlm.nih.gov/pubmed/32522440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2020.04.018 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|